Health

Eli Lilly's orforglipron has redefined obesity therapeutics, achieving up to 28% average body weight loss in pivotal Phase 3 ATTAIN-1...

Treatment-resistant depression (TRD), afflicting 30% of 21 million U.S. MDD cases, gains a standalone warrior: FDA's January 21, 2025, approval...

Lung cancer, claiming 1.8 million lives yearly, witnesses vaccine revolutions: mRNA platforms repurpose COVID-19 tech for neoantigen targeting, while LungVax...

As 2025 draws to a close, biomedical and materials science frontiers ignite with transformative potential: the U.S. government's ambitious push...

The FDA's May 16, 2025, clearance of Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio—the first blood test aiding Alzheimer's diagnosis—revolutionizes access...

Ozempic's semaglutide has affirmed profound heart protections in 2025's landmark studies, slashing major adverse cardiovascular events (MACE)—heart attacks, strokes, deaths—by...

Acute myeloid leukemia (AML) relapse stems from cunning cellular adaptations that shield malignant blasts from chemotherapy's assault. Recent investigations illuminate...

Glioblastoma multiforme (GBM), the most lethal primary brain cancer, claims lives rapidly due to its invasiveness and treatment barriers like...

In a move sparking widespread controversy, the Environmental Protection Agency (EPA) has greenlit multiple pesticide products incorporating per- and polyfluoroalkyl...

The 2025-2026 influenza season is off to a concerning start, with early indicators pointing to heightened severity across the United...